Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 2/20 | 0.31 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573145 | 0.84 | RARB (0.34) | PLA2G1BPLA2G2ARARBRARAKDM4E | |
| SCHEMBL1573088 | 0.84 | RARB (0.34) | PLA2G1BPLA2G2ARARBRARAKDM4E | |
| SCHEMBL4500962 | 0.80 | HTT (0.37) | KDM4EMEN1KMT2A | |
| SCHEMBL4514569 | 0.80 | MAPT (0.36) | KDM4EKMT2A | |
| SCHEMBL4516631 | 0.79 | ALDH1A1 (0.36) | PLA2G1BPLA2G2AKDM4EMEN1KMT2A | |
| SCHEMBL4500669 | 0.77 | LMNA (0.34) | KDM4EMEN1KMT2A | |
| SCHEMBL1573232 | 0.77 | ALDH1A1 (0.33) | PLA2G1BPLA2G2AKDM4EKMT2A | |
| SCHEMBL4508201 | 0.75 | MAPT (0.38) | RARBRARAKDM4EMEN1KMT2A | |
| SCHEMBL13918705 | 0.73 | MAPT (0.35) | KDM4EMEN1KMT2A | |
| SCHEMBL3947583 | 0.72 | ALDH1A1 (0.36) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | PLA2G1B 1236/4885PLA2G2A 1138/4885RARB 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.